NASDAQ:PHVS Pharvaris (PHVS) Stock Price, News & Analysis → Forget Bitcoin: This $8 Stock Is the Next Big Thing (From Behind the Markets) (Ad) Free PHVS Stock Alerts $20.35 -1.36 (-6.26%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$19.53▼$21.7050-Day Range$18.42▼$25.9952-Week Range$8.20▼$33.00Volume33,049 shsAverage Volume58,758 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$31.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Pharvaris alerts: Email Address Pharvaris MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside54.8% Upside$31.50 Price TargetShort InterestHealthy0.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.60Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.39) to ($2.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.94 out of 5 stars 3.3 Analyst's Opinion Consensus RatingPharvaris has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePharvaris has only been the subject of 3 research reports in the past 90 days.Read more about Pharvaris' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.30% of the float of Pharvaris has been sold short.Short Interest Ratio / Days to CoverPharvaris has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharvaris has recently increased by 31.31%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPharvaris does not currently pay a dividend.Dividend GrowthPharvaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHVS. Previous Next 0.8 News and Social Media Coverage News SentimentPharvaris has a news sentiment score of -0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Pharvaris this week, compared to 2 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pharvaris insiders have not sold or bought any company stock.Percentage Held by Insiders11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Pharvaris' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pharvaris are expected to decrease in the coming year, from ($2.39) to ($2.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharvaris is -7.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharvaris is -7.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharvaris has a P/B Ratio of 4.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pharvaris' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About Pharvaris Stock (NASDAQ:PHVS)Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Read More PHVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHVS Stock News HeadlinesMay 13, 2024 | globenewswire.comPharvaris to Present Clinical and Nonclinical Data at Upcoming CongressesMay 13, 2024 | americanbankingnews.comWedbush Analysts Reduce Earnings Estimates for Pharvaris (NASDAQ:PHVS)May 13, 2024 | americanbankingnews.comPharvaris (NASDAQ:PHVS) Given New $31.00 Price Target at WedbushMay 13, 2024 | americanbankingnews.comQ2 2024 Earnings Forecast for Pharvaris Issued By Leerink Partnrs (NASDAQ:PHVS)May 10, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | markets.businessinsider.comPharvaris’s Promising Drug Candidate Deucrictibant Bolsters Buy RatingMay 9, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Pharvaris (PHVS)May 9, 2024 | msn.comPHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024May 8, 2024 | globenewswire.comPharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateApril 15, 2024 | markets.businessinsider.comPharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE TreatmentApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid FinancialsApril 12, 2024 | finance.yahoo.comPharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth PlansApril 12, 2024 | investing.comPharvaris appoints new CFO to bolster financial strategyApril 11, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong Clinical Progress and Financial StabilityApril 11, 2024 | seekingalpha.comPHVS Pharvaris N.V.April 10, 2024 | investorplace.comPHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023April 10, 2024 | globenewswire.comPharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 10, 2024 | globenewswire.comPharvaris Appoints David Nassif, J.D., as Chief Financial OfficerApril 4, 2024 | globenewswire.comPharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceMarch 18, 2024 | globenewswire.comPharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesMarch 6, 2024 | globenewswire.comPharvaris to Present Deucrictibant Clinical Data at Upcoming CongressesMarch 5, 2024 | globenewswire.comPharvaris to Participate in the Leerink Global Biopharma Conference 2024February 26, 2024 | markets.businessinsider.comPharvaris Buy Rating Affirmed on Strong Phase 2 Data and Market Positioning for HAE TreatmentFebruary 25, 2024 | msn.comPharvaris N.V. (PHVS) Price Target Increased by 6.19% to 34.97See More Headlines Receive PHVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/18/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PHVS CUSIPN/A CIK1830487 Webwww.pharvaris.com Phone31-71-203-6410FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Target$31.50 High Stock Price Target$50.00 Low Stock Price Target$11.00 Potential Upside/Downside+54.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.67% Return on Assets-37.38% Debt Debt-to-Equity RatioN/A Current Ratio20.52 Quick Ratio20.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book4.12Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-3.02 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Berndt Axel Edvard Modig CPA (Age 65)M.B.A., Co-Founder, CEO & Executive Director Comp: $565.02kMs. Anna Nijdam M.Sc. (Age 43)R.A., Head of Strategic Finance & Principal Accounting Officer Key CompetitorsGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPProcaps GroupNASDAQ:PROCView All CompetitorsInstitutional OwnershipBain Capital Life Sciences Investors LLCSold 600,938 shares on 5/16/2024Ownership: 0.000%venBio Partners LLCSold 630,200 shares on 5/15/2024Ownership: 0.000%Price T Rowe Associates Inc. MDSold 84,783 shares on 5/15/2024Ownership: 0.000%View All Institutional Transactions PHVS Stock Analysis - Frequently Asked Questions Should I buy or sell Pharvaris stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PHVS shares. View PHVS analyst ratings or view top-rated stocks. What is Pharvaris' stock price target for 2024? 4 Wall Street analysts have issued 1-year target prices for Pharvaris' shares. Their PHVS share price targets range from $11.00 to $50.00. On average, they expect the company's stock price to reach $31.50 in the next twelve months. This suggests a possible upside of 54.8% from the stock's current price. View analysts price targets for PHVS or view top-rated stocks among Wall Street analysts. How have PHVS shares performed in 2024? Pharvaris' stock was trading at $28.05 at the beginning of the year. Since then, PHVS shares have decreased by 27.5% and is now trading at $20.35. View the best growth stocks for 2024 here. When is Pharvaris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our PHVS earnings forecast. How were Pharvaris' earnings last quarter? Pharvaris (NASDAQ:PHVS) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.56). When did Pharvaris IPO? Pharvaris (PHVS) raised $126 million in an initial public offering on Friday, February 5th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers. Who are Pharvaris' major shareholders? Pharvaris' stock is owned by many different retail and institutional investors. Top institutional investors include venBio Partners LLC (0.00%), Bain Capital Life Sciences Investors LLC (0.00%) and Price T Rowe Associates Inc. MD (0.00%). How do I buy shares of Pharvaris? Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHVS) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.